Volume | 43,999,118 |
|
|||||
News | - | ||||||
Day High | 0.1947 | Low High |
|||||
Day Low | 0.166 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.1708 | 0.166 | 0.1947 | 0.18 | 0.17 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
34,148 | 43,999,118 | US$ 0.1826563 | US$ 8,036,716 | - | 0.0512 - 1.22 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:56 | 22 | US$ 0.1822 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.14M | 50.76M | - | 9.76M | -41.3M | -0.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Date | Time | Source | News Article |
---|---|---|---|
3/08/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
3/05/2024 | 06:00 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
3/01/2024 | 16:30 | Edgar (US Regulatory) | Form 8-K - Current report |
2/16/2024 | 15:13 | Edgar (US Regulatory) | Form 8-K - Current report |
12/01/2023 | 16:25 | Edgar (US Regulatory) | Form 8-K - Current report |
11/30/2023 | 07:10 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
11/14/2023 | 20:00 | PR Newswire (Canada) | FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL.. |
11/08/2023 | 16:03 | Edgar (US Regulatory) | Form 8-K - Current report |
10/05/2023 | 16:03 | Edgar (US Regulatory) | Form 8-K - Current report |
9/21/2023 | 06:30 | PR Newswire (Canada) | FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA.. |
8/14/2023 | 15:55 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
8/14/2023 | 15:53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1621 | 0.1986 | 0.1522 | 0.1723649 | 46,191,214 | 0.0201 | 12.40% |
1 Month | 0.0836 | 0.254 | 0.071 | 0.1470403 | 87,652,057 | 0.0986 | 117.94% |
3 Months | 0.10 | 0.254 | 0.0512 | 0.1183063 | 62,703,230 | 0.0822 | 82.20% |
6 Months | 0.3289 | 0.5144 | 0.0512 | 0.1254682 | 33,668,165 | -0.1467 | -44.60% |
1 Year | 0.479 | 1.22 | 0.0512 | 0.1606955 | 18,267,265 | -0.2968 | -61.96% |
3 Years | 120.75 | 228.00 | 0.0512 | 21.42 | 9,112,344 | -120.57 | -99.85% |
5 Years | 1,186.50 | 1,273.50 | 0.0512 | 70.62 | 9,680,386 | -1,186.32 | -99.98% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |